



Sociedad Española  
de Reumatología -  
Colegio Mexicano  
de Reumatología

# Reumatología Clínica

www.reumatologiaclinica.org



## Special Article

### Myo-Spain: Spanish Registry of patients with idiopathic inflammatory myopathy. Methodology<sup>☆</sup>



Tatiana Cobo-Ibáñez,<sup>a</sup> Carlos Sánchez-Piedra,<sup>b,\*</sup> Laura Nuño-Nuño,<sup>c</sup> Iván Castellví,<sup>d</sup> Irene Carrión-Barberà,<sup>e</sup> Fredeswinda Romero-Bueno,<sup>f</sup> Javier Narváez,<sup>g</sup> Ernesto Trallero-Araguás,<sup>h</sup> Eva Tomero,<sup>i</sup> María Esther Ruiz-Lucea,<sup>j</sup> Carmen Larena,<sup>k</sup> Carmen Carrasco Cubero,<sup>l</sup> Vega Jovaní,<sup>m</sup> Carmen Barbadillo,<sup>n</sup> Francisca Sivera,<sup>o</sup> Joaquín Belzunegui,<sup>p</sup> Ana Pérez Gómez,<sup>q</sup> Alejandro Gómez Gómez,<sup>a</sup> Esmeralda Delgado-Frías,<sup>r</sup> José María Pego-Reigosa,<sup>s</sup> Beatriz Joven,<sup>t</sup> Mónica Ibáñez,<sup>u</sup> Olga Martínez-González,<sup>v</sup> Alberto Ruiz-Román,<sup>w</sup> Jordi Camins,<sup>x</sup> Rafaela Ortega-Castro,<sup>y</sup> Pilar Trenor Larra,<sup>z</sup> Marina Rodríguez López,<sup>aa</sup> Mercedes Freire,<sup>bb</sup> Patricia Alcocer,<sup>cc</sup> Susana Holgado,<sup>dd</sup> Iñigo Rúa-Figueroa,<sup>ee</sup> Nuria Lozano,<sup>ff</sup> Julia Martínez-Barrio<sup>gg</sup>

<sup>a</sup> Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain

<sup>b</sup> Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain

<sup>c</sup> Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain

<sup>d</sup> Servicio de Reumatología, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain

<sup>e</sup> Servicio de Reumatología, Hospital del Mar, Barcelona, Spain

<sup>f</sup> Servicio de Reumatología, Hospital Fundación Jimenez Díaz, Madrid, Spain

<sup>g</sup> Servicio de Reumatología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

<sup>h</sup> Servicio de Reumatología, Hospital Vall d'Hebron, Barcelona, Spain

<sup>i</sup> Servicio de Reumatología, Hospital La Princesa, Madrid, Spain

<sup>j</sup> Servicio de Reumatología, Hospital Universitario de Basurto, Bilbao, Spain

<sup>k</sup> Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>l</sup> Servicio de Reumatología, Hospital Infanta Cristina, Badajoz, Spain

<sup>m</sup> Servicio de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain

<sup>n</sup> Servicio de Reumatología, Hospital Puerta de Hierro, Madrid, Spain

<sup>o</sup> Servicio de Reumatología, Hospital General Universitario de Elda, Elda, Spain

<sup>p</sup> Servicio de Reumatología, Hospital Universitario Donostia, San Sebastián, Spain

<sup>q</sup> Servicio de Reumatología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain

<sup>r</sup> Servicio de Reumatología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

<sup>s</sup> Servicio de Reumatología, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, Grupo IRIDIS (Investigation in Rheumatology and Immunemediated Diseases) Instituto de Investigación Sanitaria Galicia Sur (IISGS)

<sup>t</sup> Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain

<sup>u</sup> Servicio de Reumatología, Hospital Universitario Son Llàtzer, Mallorca, Spain

<sup>v</sup> Servicio de Reumatología, Hospital de Salamanca, Salamanca, Spain

<sup>w</sup> Servicio de Reumatología, Hospital Virgen del Rocío, Sevilla, Spain

<sup>x</sup> Servicio de Reumatología, Hospital General de Granollers, Granollers, Spain

<sup>y</sup> Servicio de Reumatología, Hospital Universitario Reina Sofía, Universidad de Córdoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain

<sup>z</sup> Servicio de Reumatología, Hospital Clínico Universitario de Valencia, Valencia, Spain

<sup>aa</sup> Servicio de Reumatología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

<sup>bb</sup> Servicio de Reumatología, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

<sup>cc</sup> Servicio de Reumatología, Hospital Universitario HM Sanchinarro, Madrid, Spain

<sup>dd</sup> Servicio de Reumatología, Hospital Germans Trias i Pujol, Barcelona, Spain

<sup>ee</sup> Servicio de Reumatología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain

<sup>ff</sup> Servicio de Reumatología, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

<sup>gg</sup> Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain

## ARTICLE INFO

### Article history:

Received 14 December 2020

Accepted 27 January 2021

## ABSTRACT

**Objectives:** To describe the methods of the Spanish Registry of patients with idiopathic inflammatory myopathy (IIM) (Myo-Spain), as well as its strengths and limitations. The main objective of the project is to analyse the evolution and clinical management of a cohort of patients with IIM.

<sup>☆</sup> Please cite this article as: Cobo-Ibáñez T, Sánchez-Piedra C, Nuño-Nuño L, Castellví I, Carrión-Barberà I, Romero-Bueno F, et al. Myo-Spain: Registro de pacientes con miopatía inflamatoria idiopática de España. Metodología. Reumatol Clín. 2022;18:253–259.

\* Corresponding author.

E-mail address: carlos.sanchez@ser.es (C. Sánchez-Piedra).

**Keywords:**

Idiopathic inflammatory myopathy  
Myositis  
Dermatomyositis  
Polymyositis  
Inclusion body myositis  
Immune-mediated necrotising myopathy

**Methods:** Observational, longitudinal, ambispective and multicentre study of a cohort of patients with IIM seen in rheumatology units in Spain. All patients with a diagnosis of IMM will be included in the regular follow-up of the participating centres, regardless of age on initiation of the process. Incident cases will be all patients who at the beginning of the study have been diagnosed for less than 12 months and prevalent cases for more than 12 months. The registry will include data from the visit at baseline, one year and two years. Socio-demographic, clinical, analytical variables, complications, comorbidities, association with other rheumatic diseases, hospital admissions, mortality and treatments will be collected. In addition, indices, scales and questionnaires of activity, muscle involvement, damage, disability, and quality of life will be determined. The recruitment period will be 23 months. The purpose is to obtain a cohort of 400 patients with IMM.

**Conclusions:** Myo-Spain registry provides the opportunity to develop a cohort of incident and prevalent patients with IMM in Spain. Myo-Spain will be able to assess in detail the clinical characteristics of the disease at different times. The comprehensive information collected during the visits is expected to provide a broad source of data for future analysis.

© 2021 Published by Elsevier España, S.L.U.

## Myo-Spain: Registro de pacientes con miopatía inflamatoria idiopática de España. Metodología

### R E S U M E N

**Palabras clave:**

Miopatía inflamatoria idiopática  
Miositis  
Dermatomiositis  
Polimiositis  
Miositis por cuerpo de inclusión  
Miopatía necrotizante inmunomediada

**Objetivos:** Describir la metodología del Registro de pacientes con miopatía inflamatoria idiopática (MII) de España (Myo-Spain), así como sus fortalezas y limitaciones. El objetivo principal del proyecto es analizar la evolución y el manejo clínico de una cohorte de pacientes con MII.

**Material y método:** Estudio observacional, longitudinal, ambispectivo y multicéntrico de una cohorte de pacientes con MII atendidos en servicios de Reumatología de España. Se incluirán todos los pacientes con diagnóstico de MII en seguimiento habitual por los centros participantes, sin tener en cuenta la edad de inicio del proceso. Los casos incidentes serán todos los pacientes que al inicio del estudio en cada centro estén diagnosticados desde hace menos de 12 meses y casos prevalentes desde hace más de 12 meses. Se construirá un registro en el que se incluirán los datos de la visita basal, del año y dos años. Se recogerán variables socio-demográficas, clínicas, analíticas, complicaciones, comorbilidad, asociación con otras enfermedades reumáticas, ingresos hospitalarios, mortalidad y tratamientos. Además, se determinarán índices, escalas y cuestionarios de actividad, afectación muscular, daño, discapacidad y calidad de vida. El periodo de reclutamiento será de 23 meses. El propósito es conseguir una cohorte de 400 pacientes con MII.

**Conclusiones:** El estudio Myo-Spain constituye la oportunidad para desarrollar una cohorte de pacientes incidentes y prevalentes con MII en España. Myo-Spain permitirá evaluar en detalle las características clínicas de la enfermedad en diferentes momentos. Se espera que la información exhaustiva recogida en las visitas suponga una amplia fuente de datos para futuros análisis.

© 2021 Publicado por Elsevier España, S.L.U.

## Introduction

Idiopathic inflammatory myopathies (IIM) form part of a heterogeneous group of diseases of autoimmune origin characterised by non-suppurative inflammation of the skeletal muscles, progressive muscle weakness and variable expressivity in different organs and systems.<sup>1</sup> IIM are rare, with a mean incidence ranging from 1 to 19 cases/million inhabitants/year,<sup>2,3</sup> and vary according to geographical area, methodology and classification criteria. A study on the estimated incidence in Spain between 1997–2004 showed an incidence rate of 8.9 new cases/million inhabitants/year (95% confidence interval [CI] 8.6–9.2), with a higher incidence of dermatomyositis (DM) than polymyositis (PM).<sup>4</sup> The aetiology and predisposing factors for developing IIM are still not entirely clear. They are currently considered immune-mediated disorders, possibly triggered by environmental factors in genetically predisposed individuals.<sup>5</sup> IIM presents with a wide variety of clinical manifestations; muscle weakness secondary to chronic inflammation of striated muscle is characteristic. Other organs affected include the skin, joints, lung, gastrointestinal tract, and heart. Complications include infections and cancers.<sup>6–8</sup> Although the prognosis has improved substantially in recent decades, mortality has increased with respect to the general population.<sup>9</sup> Furthermore, at least one third of patients are moderately or severely disabled, mainly due to

pulmonary involvement, the development of calcinosis and muscle weakness.<sup>10</sup>

The identification of specific and associated antibodies, access to imaging techniques such as magnetic resonance imaging and ultrasound, improvements in the interpretation of muscle biopsy and the development of new classification criteria in recent decades have given us a better understanding of this group of diseases.<sup>11</sup>

However, the heterogeneity of their clinical manifestations, their evolution and prognosis, along with their low prevalence and incidence, make study of these diseases difficult. In Spain, prospective studies are limited, especially those that include all IIM subtypes. No information is available on disease activity, severity, disability, quality of life, treatment management or prognostic factors. In addition, it has not been studied whether the disease behaves differently when comparing patients who meet the new American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) classification criteria at diagnosis with those who meet them during follow-up, or those who never meet them.

Therefore, the Myo-Spain project (Spanish Registry of patients with idiopathic inflammatory myopathy (IIM)) was set up with the main objective of analysing the evolution and management of a cohort of patients with IIM attended in rheumatology departments

in Spain. This paper describes the project's methodology and potential strengths and limitations.

**Methodology**

*General design*

An observational, longitudinal, ambispective and multicentre study. An initial follow-up of two years has been proposed, which is expected to be longer to achieve the project's main objective (to study the evolution and management of IIM). The full study protocol is available at <https://myospain.ser.es>.

*Reference population*

Patients diagnosed with any type of IIM under routine follow-up by rheumatology services, regardless of age at onset.

Two groups of patients have been considered according to time of diagnosis. Incident cases will be all patients who at the start of the study in each centre have been diagnosed for less than 12 months and prevalent cases, all those diagnosed for more than 12 months.

*Study population. Inclusion and exclusion criteria*

1. Inclusion criteria

- Patients with a diagnosis of IIM, according to the judgement of the attending physician, and under active follow-up. Types of IIM can be DM, PM, amyopathic DM, hypomyopathic DM, inclusion body myositis (IBM), immune-mediated necrotising myopathy (IMNM), juvenile myopathies, anti-synthetase syndrome, other overlapping syndromes with myositis and unclassifiable.
- No age group is excluded from the study. The questionnaires will be answered by the parents or guardians of non-mature minors.

2. Exclusion criteria

- Patients who, in the opinion of the investigator, have difficulties in attending the visits or completing the forms.
- Individuals diagnosed with myopathies of toxic or infectious cause or secondary to neuromuscular disease.
- When complete data required for the classification criteria, or a final medical diagnosis are not available.

*Selection of participating centres*

All hospitals with specialist rheumatology care belonging to the Spanish Society of Rheumatology Systemic Autoimmune Diseases Working Group (GT EASSER) and interested members of the Spanish Society of Rheumatology (SER) were invited to participate. An online survey was conducted (June 2017) that obtained information on the experience and casuistry of IIM. A pre-selection was then made using an application form sent by interested centres (7 March to 10 April 2018), detailing recruitment capacity and experience in the management of IIM. The centres were selected over the month of June 2018. A total of 32 centres are eventually participating in the project (Table 1).

*Patient recruitment*

The recruitment period is 23 months. The aim is to recruit all patients with a diagnosis of IIM who meet the inclusion criteria with none of the exclusion criteria. All patients must provide their informed consent prior to entering the study.

**Table 1**  
List of participating centres.

Participating hospital	Autonomous community
Hospital Universitario de Badajoz	Extremadura
Hospital Universitario de la Santa Creu i Sant Pau	Catalonia
Complejo Asistencial Universitario de Salamanca	Castilla y León
Hospital Universitario 12 de Octubre	Community of Madrid
Hospital del Mar	Catalonia
Hospital General Universitario Gregorio Marañón	Community of Madrid
Hospital Universitario Puerta de Hierro	Community of Madrid
Hospital General Universitario de Alicante	Valencian Community
Hospital Universitario de Bellvitge	Catalonia
Hospital General Universitario de Elda	Valencian Community
Hospital Universitario Virgen del Rocío	Andalusia
Complejo Hospitalario Universitario A Coruña	Galicia
Hospital Universitario Ramón y Cajal	Community of Madrid
Hospital Universitario de la Princesa	Community of Madrid
Hospital Universitario de Basurto	Basque Country
Hospital Germans Trias i Pujol	Catalonia
Hospital General de Granollers	Catalonia
Hospital Universitario de Gran Canaria Doctor Negrín	Canary Islands
Hospital Universitario Infanta Sofía	Community of Madrid
Hospital Universitario la Paz	Community of Madrid
Hospital Universitario Fundación Jiménez Díaz	Community of Madrid
Hospital Universitario HM Sanchinarro	Community of Madrid
Complejo Hospitalario Universitario de Vigo	Galicia
Hospital Universitario Son Llàtzer	Balearic Islands
Hospital Universitario Virgen de la Arrixaca	Community of Murcia
Hospital Universitario de Canarias	Canary Islands
Hospital Universitario Donostia	Basque Country
Hospital Universitario Reina Sofía	Andalusia
Hospital Clínico Universitario de Valencia	Valencian Community
Complejo Hospitalario Universitario de Santiago	Galicia
Hospital Universitario Vall d'Hebron	Catalonia
Hospital Universitario Príncipe de Asturias	Community of Madrid

Patients are invited to participate consecutively at one of their regular visits to the rheumatologist. Patient access to rheumatology services for diagnosis and follow-up is as routine (emergency department, primary care and interconsultation with other specialties such as dermatology, pulmonology, or neurology). The study has been opened to collaborating researchers from other specialties such as neurology and internal medicine, although rheumatology will coordinate in each centre. The recruitment period began in June 2019.

The electronic Data Collection Form (DCF) allocates an identification code in the study to each of the participants, to maintain data confidentiality, in accordance with current legislation (EU Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016 on Data Protection [RGPD]), as well as all applicable Spanish and European legislation on privacy and personal data protection. The study has been approved by the reference (Hospital La Paz, Madrid) clinical research ethics committee (CREC) and by each of the CEICs of the participating centres.

*Data collection*

An electronic DCF specific to Myo-Spain has been created to which each participating centre has access. Clinical information is collected retrospectively (prevalent cases) from the clinical history, and prospectively (prevalent and incident cases), obtained from baseline and follow-up visits, after one and two years.

## Variables and measurements

Multiple analyses with different outcome variables are necessary to meet the objectives of the project, and therefore no specific primary outcome variable has been defined.

Variables and measurements will be collected on the online DCF, both at baseline and at the follow-up visit, after one and two years.

### 1 General, inclusion and sociodemographic data

These variables include date of birth, sex, race, educational level, the patient's IIM classification criteria, type of IIM, date of onset of IIM symptoms, data of diagnosis of IIM, and date of visit. In addition, the date and reason for loss to follow-up will be recorded at the follow-up visits of year 1 and year 2 for patients who drop out of the study.

### 2 Classification criteria

Variables relating to the classification criteria are recorded, such as the form of onset of IIM (acute [0–14 days from onset], subacute [ $>14$  days to  $\leq 2$  months] or insidious [ $>2$  months to years]), weakness in the limbs and in the flexor-extensor musculature of the neck, muscle pain on pressure or spontaneous muscle pain, elevated muscle enzyme levels, presence of typical DM rash, joint, digestive and systemic manifestations, muscle biopsy, electromyography and magnetic resonance imaging results.

### 3 Disease activity

This includes the Myositis Disease Activity Assessment (MYOACT) where the physician assesses disease activity over the last four weeks using a 10-cm visual analogue scale (VAS) in seven organs/systems (constitutional, cutaneous, skeletal, gastrointestinal, pulmonary, cardiac, and muscular). It also includes global extramuscular assessment and global MYOACT assessment (muscular and extramuscular) in the last four weeks on a 0–10-cm VAS<sup>12,13</sup>. It also includes the presence of specific variables at cutaneous (ulceration, panniculitis, erythematous rash, periorbital capillary changes, alopecia, mechanic's hands, cutaneous vasculitis, sclerodactyly [localised thickening and hardening of the skin of the fingers and toes], Raynaud's phenomenon and others), skeletal (arthritis and arthralgia), gastrointestinal (dysphagia or dysmotility), pulmonary (diffusing capacity for carbon monoxide [DLCO], forced vital capacity [FVC], interstitial lung disease patterns on high-resolution computed tomography [HRCT], chronic home oxygen requirement) and cardiac (pericarditis, myocarditis and arrhythmias) levels. Finally, it includes the physician and patient/parent or guardian global disease assessment at the time of the visit (0–10-cm VAS), and Manual Muscle Testing in eight muscle groups (MMT-8)<sup>12,13</sup>.

### 4 Functional capacity

The scores are collected of the Health Assessment Questionnaire for functional status in adults, and of the childhood HAQ (CHAQ) relating to the week prior to the visit<sup>12,13</sup>.

### 5 Damage

Damage means persistent changes in anatomy, physiology, pathology, or function of any cause since the onset of myositis and present for at least six months. The Myositis Damage Index (MDI) is included, used by the clinician to assess the severity of damage by 10-cm VAS in 11 organs/systems (muscular, skeletal, cutaneous, gastrointestinal, pulmonary, cardiovascular,

peripheral vascular, endocrine, ocular, infection, and malignancy). The global assessment of the severity of damage (0–10-cm VAS) of the MDI is also recorded<sup>12,13</sup>. The presence and date of diagnosis of specific variables of damage at cutaneous (calcinosis, lipodystrophy), pulmonary (pulmonary arterial hypertension), cardiovascular (arterial hypertension, ischaemic heart disease), peripheral vascular (venous or arterial thrombosis), endocrine (diabetes mellitus), serious infection (including location), malignant neoplasms (including type), mortality (including cause) levels are recorded. Finally, the physician and patient/parent or guardian global assessment of damage at the time of the visit (0–10 cm VAS) is included<sup>12,13</sup>.

### 6 Laboratory

Muscle enzyme levels (CPK, GOT, GPT and LDH), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and ferritin are collected.

### 7 Antibodies

Information is collected on the presence of specific myositis-associated antibodies (anti-synthetase, anti-MDA5, anti-Mi-2, anti-SRP, anti-TIF1- $\gamma$ , anti-NXP2, anti-HMG-CoA reductase, anti-SAE, anti-Ku, anti-Ro, anti-RNP, anti-PM/SCL).

### 8 Other comorbidities

Information is added on comorbidities that are not included in the damage variables (dyslipidaemia, smoking and association with other autoimmune diseases).

### 9 Hospitalisation

This includes information on hospitalisations and admissions to intensive care units (date and cause).

### 10 Treatment

The main treatments used for this disease and their indication are included: glucocorticoids, antimalarials, synthetic immunosuppressants, biological and synthetic targeted immunosuppressants, intravenous immunoglobulins and plasmapheresis (start date, end date and reason for discontinuation). Other less common treatments such as lung transplantation or direct haemoperfusion with polymyxin B are also included.

### 11 Quality of life

Information from the 12-Item Short-Form Health Survey (SF-12) quality of life measure is collected<sup>12,13</sup>.

Table 2 shows the measures taken at each visit of the study.

### Sample size

The sample size was not estimated, taking the objectives of the registry into account. All patients from each participating centre who meet the inclusion criteria are anticipated to be included in the study. Based on a previous study of interested centres, the total number of patients is estimated to be around 400. One hundred and eighty-six patients have been included in the first year of recruitment.

**Table 2**  
Measures taken at each visit of the study.

Measures	Visits		
	0	1	2
Informed consent	X		
Inclusion and sociodemographic data	X		
Loss to follow-up		X	X
General data	X	X	X
Classification criteria	X	X	X
Disease activity			
MYOACT	X	X	X
Variables at cutaneous, joint, gastrointestinal, pulmonary, and cardiac levels	X	X	X
Physician global damage assessment	X	X	X
Patient/parent or guardian global damage assessment	X	X	X
MMT-8	X	X	X
HAQ or cHAQ	X	X	X
Damage			
MDI	X	X	X
Variables at the cutaneous, pulmonary, cardiovascular, peripheral vascular, endocrine levels, severe infection, malignant neoplasms, and mortality	X	X	X
Physician global damage assessment	X	X	X
Patient/parent or guardian global damage assessment	X	X	X
Laboratory	X	X	X
Antibodies	X	X	X
Other comorbidities	X	X	X
Hospitalization	X	X	X
Treatment	X	X	X
SF-12	X	X	X

cHAQ: child HAQ; HAQ: Health Assessment Questionnaire; MDI: Myositis Damage Index; MYOACT: Myositis Disease Activity Assessment; MMT-8: Manual Muscle Testing of eight muscle groups; SF-12: 12-Item Short-Form Health Survey.

### Quality control of the database

Annual online monitoring will take place. Each year, the consistency of all new data recorded in the data collection platform will be reviewed, paying special attention to the variables that gather information relating to the study objectives. Only patients who meet >80% of the visit variables will be considered eligible for analysis.

The procedures have been standardised in addition to the monitoring process. This standardisation has been included in a Myo-Spain investigator's manual available to all investigators participating in the study.

### Visit reminder

Periodic (every two to three months) reminder and project status emails are sent to all participating centres during the inclusion period (V0). In addition, a reminder email is sent systematically from the online DCF to each centre's investigators, notifying them closely in advance (in the month prior to the theoretical date) of the follow-up visits (V1 and V2), to ensure that the visits take place and patient information is gathered.

### Discussion

This paper describes the methodology of the Myo-Spain registry. The project represents the creation of a Spanish multicentre cohort of incident and prevalent patients with any type of IIM, with a prospective two-year follow-up.

Several registries have been established at the international level to investigate different aspects of IIM. The multicentre EuroMyositis registry was created in 1999 and currently involves more than 20 countries, primarily in Europe. The registry seeks to obtain uniform longitudinal data on juvenile and adult myositis to gain a better understanding of the course and prognosis of the disease. There is a mandatory data collection area containing basic information present at some time over the duration of the

myositis, and another area, which is not mandatory to complete, corresponding to individual visits to monitor the course of the disease (activity and damage, muscle weakness, treatment, antibodies, and biopsy results). The registry has more than 3000 participants and publications have studied associations between clinical subtypes, extramuscular involvement, environmental exposure, antibodies, and drugs<sup>14,15</sup>. In addition, this cohort together with the UK and Ireland cohort, the Juvenile Dermatomyositis Research Group (JDRG), validated the new EULAR/ACR classification criteria<sup>11,16</sup>.

The American Myositis Patient Association launched the MYOVISION national registry in 2010. From December 2010 to July 2012, 1806 patients with IIM (PM, DM, IBM) were included in this registry and agreed to complete a paper or online survey with 83 questions on demographics, work or school, leisure activities, environmental exposure, disease exposure and health-related quality of life. Several cross-sectional studies on environmental exposure and quality of life have been published<sup>17,18</sup>. From the US multicentre Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry, which included patients with childhood rheumatic diseases between 2010 and 2014, cross-sectional studies of the 688-patient juvenile DM cohort have been published on clinical characteristics and the association between exposure to ultraviolet radiation and disease severity<sup>19,20</sup>. Because of the limitations in the number of variables, in the information on treatments, and in the data collection process that was not systematic at each visit, the new CARRA registry, which was limited to juvenile idiopathic arthritis, was created in 2015<sup>21</sup>.

The American and European NETwork of Antisynthetase Syndrome (AENEAS) collaborative cohort is part of an international, multicentre, retrospective study, started in 2014, which includes patients with antisynthetase syndrome with at least six months' follow-up. The publications in this cohort have focused on the form of presentation of the disease, progression, outcomes, and its specific behaviour, according to the presence of the different anti-synthetase antibodies or specific manifestations such as arthritis<sup>22–24</sup>.



We should highlight three initiatives at the national level. The first was internal medicine's registry of patients with anti-synthetase syndrome of the Systemic Autoimmune Diseases Study Group (GEAS), which provided information on manifestations and long-term outcomes in patients with anti-jo1 antibodies<sup>25</sup>. The second was the registry of patients with inflammatory myopathy of the Madrid Rheumatology Society (REMICAM), with the participation of 12 rheumatology units of the Community of Madrid and retrospective collection of clinical and mortality data for patients under follow-up at some point between 1980 and December 2014. This registry has provided information on mortality, long-term pulmonary outcomes, overlap syndromes with myositis and juvenile forms<sup>26–29</sup>. Finally, the national registry of patients with MDA5 syndrome (MEDRA5), a multicentre and multidisciplinary registry that aims to understand the natural history of MDA5 syndrome, and has collected clinical data on these patients retrospectively until December 2019.

As a strength of the project, and unlike most of the above-mentioned registries, Myo-Spain will carry out a prospective protocolised follow-up with annual visits of all patients. This was initially planned for two years, but is expected to be longer, given that IIM are infrequent and heterogeneous diseases and greater follow-up is required to determine their progression and management (the main objective of the project). All registry variables have been standardised, the data will be strictly monitored and patients who do not reach 80% of the required variables will be excluded from analysis. Although data from follow-up visits can also be collected prospectively in the EuroMyositis registry, this is not mandatory, and the incidence of new manifestations over time may be underestimated. In addition, in the early years of the registry, not all current subtypes of IIM, such as IMNM, had been established and some myositis-specific antibodies had not been discovered, and therefore a percentage of patients may be incorrectly classified. Another strength of Myo-Spain is that from the outset it was designed with two cohorts, one with incident patients (<12 months from diagnosis) and another with prevalent patients (>12 months from diagnosis), in which all patients must be alive and under active follow-up to be included. As this is a rare disease, we decided on an extended recruitment period, increasing the likelihood of including incident cases. At the same time, we aimed to determine disease activity, damage, disability, muscle strength and quality of life using validated indices and questionnaires to assess disease status and look for associations in a more objective way. Furthermore, by including all the subtypes of IIM, we will be able to make comparisons and identify differences in our population. We will also be able to study the diagnostic usefulness of the new classification criteria in this cohort of the future classification criteria for anti-synthetase syndrome and to determine the differences between patients with complete and incomplete forms at onset of the disease.

However, our registry also has a few limitations. First, it was not designed to be representative of the geographical distribution of IIM at the national level. This cohort does not include patients from all autonomous communities; to be specific, there are no data from centres in Aragón, Asturias, Cantabria, Castilla La Mancha, La Rioja, and Navarra. Another possible limitation is patient selection bias, including patients who may have an easier follow-up or who have fewer comorbidities. To avoid this bias, the need to recruit all patients who meet the inclusion criteria per centre was considered, which also becomes a necessity due to the prevalence and incidence data of IIM. Recruitment of all patients meeting the inclusion criteria has been reinforced through regular communication with participating investigators and at meetings at the start of the study and follow-up. Although this is a project of the Spanish Society of Rheumatology and the principal investigators at each centre are rheumatologists, to minimise possible recruitment bias,

it was opened for the participation of collaborating investigators from other specialties such as internal medicine and neurology.

## Conclusions

The Myo-Spain study represents a cohort of patients with any type of IIM recruited in rheumatology units throughout Spain. This is the first prospective study of these characteristics that the SER has promoted in a rare disease. The cohort will include a group of incident patients and a group of prevalent patients, which will allow detailed assessment of the clinical characteristics of the disease at different times. It is expected that the comprehensive information collected at the visits will provide a valuable source of data for future analysis and research.

## Funding

Myo-Spain is funded by Kern Pharma (Spain), Nordic Pharma (Spain), Sandoz (Spain) and Bristol-Myers Squibb (Spain). None of these companies were involved in the study design, data collection or analysis, or in drafting this article.

## Conflict of interests

The authors have no conflict of interests to declare.

## Acknowledgements

We would like to thank Fernando Sánchez-Alonso and Nuria Montero, staff members of the Research Unit of the Spanish Society of Rheumatology who are collaborating in the development of the project.

## References

- Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). *N Engl J Med*. 1975;292:403–7.
- Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. *Rheum Dis Clin North Am*. 2002;28:723–41.
- Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. *Rheumatology (Oxford)*. 2015;54:50–63.
- Vargas-Legas H, Selva-O'Callaghan A, Campins-Martí M, Herosilla Pérez E, Grau-Junyent JM, Martínez Gómez X, et al. [Polymyositis-dermatomyositis: incidence in Spain (1997–2004)]. *Med Clin (Barc)*. 2007;129:721–4.
- Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. *Medicine (Baltimore)*. 1991;70:360–74.
- Chen JJ, Tsai WP, Wu YJ, Luo SF, Ho HH, Liou LB, et al. Infections in polymyositis and dermatomyositis: analysis of 192 cases. *Rheumatology (Oxford)*. 2010;49:2429–37.
- Marie I, Hachulla E, Cherin P, Hellot MF, Herson S, Levesque H, et al. Opportunistic infections in polymyositis and dermatomyositis. *Arthritis Rheum*. 2005;53:155–65.
- Callen JP. Relation between dermatomyositis and polymyositis and cancer. *Lancet*. 2001;357:85–6.
- Dobloug GC, Svensson J, Lundberg IE, Holmqvist M. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. *Ann Rheum Dis*. 2018;77:40–7.
- Sultan S, Ioannou Y, Moss K, Isenberg D. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. *Rheumatology*. 2002;41:22–6.
- Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Arthritis Rheum*. 2017;69:2271–82.
- Benveniste O, Rider LG, Aggarwal R, Allenbach Y, Benveniste O, Mammen AL, et al. 213th ENMC International Workshop: outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015. *Neuromusc Disord*. 2016;26:523–34.
- Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (mmt), health assessment questionnaire (haq)/childhood health assessment

- questionnaire (c-haq), childhood myositis assessment scale (cmas), myositis disease activity assessment tool (mdaat), disease activity score (das), short form 36 (sf-36), child health questionnaire (chq), physician global damage, myositis damage index (mdi), quantitative muscle testing (qmt), myositis functional index-2 (fi-2), myositis activities profile (map), inclusion body myositis functional rating scale (ibmfrs), cutaneous dermatomyositis disease area and severity index (cdasi), cutaneous assessment tool (cat), dermatomyositis skin severity index (dssi), skindex, and dermatology life quality index (dlqi). *Arthritis Care Res.* 2011;63:S118–57.
14. Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. *Ann Rheum Dis.* 2018;77:30–9.
  15. Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. *J Autoimmun.* 2019;101:48–55.
  16. McCann L, Juggins A, Maillard S, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. *Rheumatology.* 2006;45:1255–60.
  17. Parks CG, Wilkerson J, Rose KM, Faiq A, Noroozi Farhadi P, Long CS, et al. Association of ultraviolet radiation exposure with dermatomyositis in a National Myositis Patient Registry. *Arthritis Care Res (Hoboken).* 2019;72:1636–44.
  18. Feldon M, Farhadi PN, Brunner HI, Itert L, Goldberg B, Faiq A, et al. Predictors of reduced health-related quality of life in adult patients with idiopathic inflammatory myopathies. *Arthritis Care Res.* 2017;69:1743–50.
  19. Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. *Arthritis Care Res.* 2014;66:404–10.
  20. Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW, CARRA Legacy Registry Investigators. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. *Pediatr Rheumatol.* 2018;16:84.
  21. Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, et al. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. *Pediatr Rheumatol Online J.* 2017;15:30.
  22. Cavagna L, Nuno L, Scire CA, Govoni M, López Longo FJ, Franceschini F, et al. Clinical spectrum time course in anti-Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. *Medicine (Baltimore).* 2015;94:e1144.
  23. Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. *J Clin Med.* 2019;8:2013.
  24. González-Gay MA, Montecucco C, Selva-O'Callaghan A, Trallero-Araguás E, Molberg O, Andersson H, et al. Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. *Clin Exp Rheumatol.* 2018;36:44–9.
  25. Trallero-Araguás E, Grau-Junyent JM, Labirua-Iturburu A, García-Hernández FJ, Monteagudo-Jiménez M, Fraile-Rodríguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. *Semin Arthritis Rheum.* 2016;46:225–31.
  26. Nuño-Nuño L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Llorente Cubas I, et al. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. *Rheumatol Int.* 2017;37:1853–61.
  27. Nuño L, Joven B, Carreira P, Maldonado V, Larena C, Llorente I, et al. Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: descriptive analysis. *Reumatol Clín.* 2017;13:331–7.
  28. Nuño-Nuño L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Llorente-Cubas I, et al. Overlap myositis, a distinct entity beyond primary inflammatory myositis: a retrospective analysis of a large cohort from the REMICAM registry. *Int J Rheum Dis.* 2019;22:1393–401.
  29. Cobo-Ibáñez T, López-Longo F-J, Joven B, Carreira PE, Muñoz-Hernández S, Maldonado-Romero V, et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. *Clin Rheumatol.* 2019;38:803–15.